Johnson & Johnson's second quarter 2026 revenue of $25.3B beats estimates as the company raises its full-year outlook.

Johnson & Johnson reported second quarter 2026 revenue of $25.31 billion, up 6.6% year-over-year, and adjusted EPS of $2.90, an increase of 4.7%. The results surpassed analyst expectations for both revenue and earnings, driven by strong performance in the Innovative Medicine segment.

Key Highlights

• The company raised its full-year 2026 guidance, now expecting reported sales of $101.1 billion at the midpoint (up from $100.8 billion) and adjusted EPS of $11.68 at the midpoint (up from $11.55).
• Innovative Medicine operational sales grew 6.8%, led by strong performance in Oncology and Immunology products which offset an approximate 760 basis point negative impact from the decline in Stelara sales.
• The MedTech segment delivered 3.6% operational sales growth, primarily driven by products in Surgery, Cardiovascular, and Vision.